Inclusion criteria for use of peptide receptor radionuclide therapy with Lutetium-177 Dotatate in neuroendocrine tumors (NETs)

Inoperable/metastatic well-differentiated (grade 1/2) NET

Well-differentiated grade 3 NET may be considered (further data are required on response rates and survival in this newly defined subgroup)

Sufficient tumor uptake on the diagnostic somatostatin receptor-based imaging

Sufficient bone marrow reserves (grades 1 to 2 haematological toxicity usually accepted)

Creatinine clearance >50 mL/min

Karnofsky performance status >50

Expected survival >3 months

Signed informed consent

Reproduced with permission from: Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105:295. Copyright © 2017 S. Karger AG, Basel.

Graphic 116972 Version 2.0

خرید پکیج

Inclusion criteria for use of peptide receptor radionuclide therapy with Lutetium-177 Dotatate in neuroendocrine tumors (NETs)